---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Dosage"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Dosage. Topics: Investigational phase 3 regimens, Blinded dosing schedule in the phase 3 trial, Phase 2a doses and dose selection for phase 3, and Dosing in the phase 3 extension study. 4 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description/dosage"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Dosage

<a id="heading-2.1.2.10.1"></a>

## 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

### Investigational phase 3 regimens

> “Approximately 90 patients will be enrolled and randomized to receive either ADX-324 300 mg every 6 months, ADX-324 240 mg every 3 months, or placebo during the study.”

Source: [ADARx Pharmaceuticals (2025)](https://www.adarx.com/adarx-pharmaceuticals-announces-first-patient-dosed-in-phase-3-stop-hae-clinical-trial-and-orphan-drug-designation-for-adx-324-a-long-acting-sirna-in-development-for-the-prophylactic-treatment-of-her/)

<a id="topic-2.1.2.10.1-2"></a>

### Blinded dosing schedule in the phase 3 trial

> “Participants will be randomly assigned to 1 of 3 treatment groups. 1) ADX-324 300mg on day 1 (D1) + Placebo on Week 13 (W13), 2) ADX-324 240mg D1 + ADX-324 240mg W13, 3) Placebo D1 + Placebo W13.”

Source: [Health Research Authority (2025)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/stop-hae-a-phase-3-study-of-adx-324-in-hae/)

<a id="topic-2.1.2.10.1-3"></a>

### Phase 2a doses and dose selection for phase 3

> “Phase 2a doses: 122.5 mg Q6M, or 245 mg Q6M; Phase 3 dose cohorts: 300 mg Q6M or 240 mg Q3M”
> “The attack-free interval seen with these subtherapeutic doses supported our choice of doses in our ongoing STOP-HAE Phase 3 trial.”

Source: [ADARx Pharmaceuticals prospectus (2026)](https://www.sec.gov/Archives/edgar/data/1802369/000119312526403094/d903461d424b4.htm)

> “For HAE patients, 300 mg Q6M subcutaneous (SC) injection projected to maintain 80% (preferred) mean reduction target at 6-month.”

Source: [Li et al. (2026)](https://www.adarx.com/wp-content/uploads/2026/05/AAAAI-Feb-2026_ADX-poster_FINAL-v12Feb2026.pdf)

<a id="topic-2.1.2.10.1-4"></a>

### Dosing in the phase 3 extension study

> “Participants who received ADX-324 in the core study will continue to receive the same dosing regimen as in the core study (ie, ADX-324 300 mg every 6 months [Q6M] in Group 1 or 240 mg every 3 months [Q3M] in Group 2).”
> “Participants who received placebo 1.5 mL in the core study will receive ADX-324 300 mg Q6M (Group 1) and those who received placebo 1.2 mL in the core study will receive 240 mg Q3M (Group 2).”
> “In order to maintain the blind in the core study, all participants will receive an injection Q3M; participants in the Q6M regimen will alternate between ADX-324 and placebo Q3M while participants in the Q3M group will receive ADX-324 Q3M as outlined.”

Source: [Health Research Authority (2026)](https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/extension-study-of-adx-324-in-hae/)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
